Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
Inozyme Pharma (Nasdaq: INZY) has appointed Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, currently Chief Commercial Officer and Executive Vice President at Ultragenyx, brings over 20 years of commercial expertise in the biopharma industry. This appointment comes as Inozyme prepares for its transition into a commercial-stage company.
CEO Douglas A. Treco highlighted Harris's track record in launching rare disease therapies and his commercial insights as valuable assets for advancing INZ-701 through late-stage development. Harris expressed enthusiasm for INZ-701's potential in treating rare diseases affecting bone health and blood vessel function.
Harris's previous roles include senior positions at Ultragenyx, Crescendo Bioscience, Intermune, Elan Pharmaceuticals, Genentech, and Bristol-Myers Squibb. He also serves on the Board of Directors at Denali Therapeutics. Harris holds an M.B.A. from the Wharton School of Business and a B.S. from the United States Naval Academy.
Inozyme Pharma (Nasdaq: INZY) ha nominato Erik Harris nel suo Consiglio di Amministrazione, con effetto dal 3 ottobre 2024. Il signor Harris, attualmente Chief Commercial Officer e Vice Presidente Esecutivo di Ultragenyx, porta con sé oltre 20 anni di esperienza commerciale nel settore biofarmaceutico. Questa nomina arriva mentre Inozyme si prepara alla sua transizione verso una società in fase commerciale.
Il CEO Douglas A. Treco ha evidenziato il buon andamento di Harris nel lanciare terapie per malattie rare e le sue intuizioni commerciali come risorse preziose per far avanzare INZ-701 attraverso lo sviluppo in fase avanzata. Harris ha espresso entusiasmo riguardo al potenziale di INZ-701 nel trattamento di malattie rare che colpiscono la salute ossea e la funzione dei vasi sanguigni.
Le precedenti posizioni di Harris includono ruoli senior presso Ultragenyx, Crescendo Bioscience, Intermune, Elan Pharmaceuticals, Genentech e Bristol-Myers Squibb. Inoltre, è membro del Consiglio di Amministrazione di Denali Therapeutics. Harris ha conseguito un M.B.A. presso la Wharton School of Business e una laurea B.S. presso l'Accademia Navale degli Stati Uniti.
Inozyme Pharma (Nasdaq: INZY) ha designado a Erik Harris en su Junta Directiva, con efecto a partir del 3 de octubre de 2024. El Sr. Harris, actualmente Chief Commercial Officer y Vicepresidente Ejecutivo en Ultragenyx, aporta más de 20 años de experiencia comercial en la industria biofarmacéutica. Este nombramiento se produce mientras Inozyme se prepara para su transición a una empresa en etapa comercial.
El CEO Douglas A. Treco destacó el historial de Harris en el lanzamiento de terapias para enfermedades raras y sus perspectivas comerciales como activos valiosos para avanzar con INZ-701 a través del desarrollo en etapas avanzadas. Harris expresó entusiasmo por el potencial de INZ-701 en el tratamiento de enfermedades raras que afectan la salud ósea y la función de los vasos sanguíneos.
Los roles anteriores de Harris incluyen posiciones senior en Ultragenyx, Crescendo Bioscience, Intermune, Elan Pharmaceuticals, Genentech y Bristol-Myers Squibb. También forma parte de la Junta Directiva de Denali Therapeutics. Harris tiene un MBA de la Wharton School of Business y una licenciatura B.S. de la Academia Naval de los Estados Unidos.
이노자임 파마(Inozyme Pharma) (나스닥: INZY)는 에릭 해리스를 이사회에 임명했습니다, 2024년 10월 3일부로 발효됩니다. 해리스 씨는 현재 울트라제닉스(Ultragenyx)의 상업 최고 책임자(Chief Commercial Officer) 및 부사장(Executive Vice President)으로 20년 이상의 생물제약 산업에서의 상업적 전문성을 보유하고 있습니다. 이번 임명은 이노자임이 상업 단계 회사로의 전환을 준비하는 과정에서 이루어졌습니다.
CEO인 더글라스 A. 트레코(Douglas A. Treco)는 해리스의 희귀 질환 치료제 출시 이력과 상업적 통찰력이 INZ-701을 후기 개발 단계로 추진하는 데 있어 가치 있는 자산이라고 강조했습니다. 해리스는 INZ-701이 뼈 건강과 혈관 기능에 영향을 미치는 희귀 질환 치료에서의 잠재력에 대해 열정을 표현했습니다.
해리스의 이전 경력에는 울트라제닉스, 크레센도 바이오사이언스(Crescendo Bioscience), 인터뮤니(Intermune), 엘란 제약(Elan Pharmaceuticals), 젠엔텍(Genentech), 브리스톨-마이어스 스퀴브(Bristol-Myers Squibb)에서의 고위직이 포함됩니다. 또한 그는 데날리 치료제(Denali Therapeutics)의 이사회의 일원입니다. 해리스는 와튼 스쿨(Wharton School of Business)에서 MBA를, 미 해군사관학교(United States Naval Academy)에서 학사(B.S.)를 취득했습니다.
Inozyme Pharma (Nasdaq: INZY) a nommé Erik Harris à son Conseil d'Administration, effectif à partir du 3 octobre 2024. M. Harris, actuellement Chief Commercial Officer et Vice-Président Exécutif chez Ultragenyx, apporte plus de 20 ans d'expertise commerciale dans l'industrie bio-pharmaceutique. Cette nomination intervient alors qu'Inozyme se prépare à sa transition vers une entreprise en phase commerciale.
Le CEO Douglas A. Treco a souligné le parcours de Harris dans le lancement de thérapies pour des maladies rares et ses perspectives commerciales comme des atouts précieux pour faire progresser INZ-701 à travers le développement en phase avancée. Harris a exprimé son enthousiasme pour le potentiel d'INZ-701 dans le traitement de maladies rares affectant la santé osseuse et la fonction des vaisseaux sanguins.
Les précédents rôles de Harris incluent des postes de direction chez Ultragenyx, Crescendo Bioscience, Intermune, Elan Pharmaceuticals, Genentech et Bristol-Myers Squibb. Il est également membre du Conseil d'Administration de Denali Therapeutics. Harris détient un MBA de la Wharton School of Business et une licence B.S. de l'Académie Navale des États-Unis.
Inozyme Pharma (Nasdaq: INZY) hat Erik Harris in seinen Vorstand berufen, und zwar mit Wirkung zum 3. Oktober 2024. Herr Harris, der derzeit Chief Commercial Officer und Executive Vice President bei Ultragenyx ist, bringt über 20 Jahre Erfahrung in der Biopharma-Branche mit. Diese Ernennung erfolgt, während Inozyme sich auf den Übergang zu einem kommerziellen Unternehmen vorbereitet.
CEO Douglas A. Treco hob Harris' Erfolgsbilanz bei der Einführung von Therapien für seltene Krankheiten und seine kommerziellen Einsichten als wertvolle Ressourcen hervor, um INZ-701 durch die späte Entwicklungsphase voranzutreiben. Harris äußerte Begeisterung für das Potenzial von INZ-701 zur Behandlung seltener Krankheiten, die die Knochengesundheit und die Funktion der Blutgefäße beeinträchtigen.
Zu Harris' früheren Positionen gehören leitende Funktionen bei Ultragenyx, Crescendo Bioscience, Intermune, Elan Pharmaceuticals, Genentech und Bristol-Myers Squibb. Er ist zudem Mitglied des Vorstands von Denali Therapeutics. Harris hat einen MBA von der Wharton School of Business und einen B.S. von der United States Naval Academy.
- Appointment of Erik Harris, an experienced commercial leader, to the Board of Directors
- Harris brings over 20 years of biopharma industry experience, particularly in rare disease therapies
- Strategic move to prepare for transition into a commercial-stage company
- Potential advancement of INZ-701 through late-stage development
- None.
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings to Inozyme over 20 years of commercial expertise within the biopharma industry.
“It is a privilege to welcome Erik to the Inozyme Board of Directors at this exciting juncture for Inozyme as we continue to lay the groundwork for our transition into a commercial-stage company,” said Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme Pharma. “Erik’s track record of spearheading successful launches for rare disease therapies, combined with his deep commercial insights, will be invaluable as we advance INZ-701 through late-stage development and prepare to bring this important program to patients.”
Mr. Harris added: “INZ-701 holds significant promise as an important new therapy for a broad range of serious rare diseases affecting bone health and blood vessel function. I look forward to collaborating with Inozyme’s talented team as they work toward unlocking the full potential of this innovative therapy for patients who urgently need it.”
Prior to his appointment as Chief Commercial Officer, Mr. Harris served as the Senior Vice President and Head of North American Commercial Operations at Ultragenyx. Before joining Ultragenyx, he spent six years at Crescendo Bioscience, most recently as Vice President of Commercial. Earlier in his career, Mr. Harris served as Vice President of Marketing at Intermune, Inc., and held positions in the commercial organizations at Elan Pharmaceuticals, Inc., Genentech, Inc., and Bristol-Myers Squibb Company. He currently serves on the Board of Directors at Denali Therapeutics.
At the start of his professional career, Mr. Harris served as a Lieutenant Commander in Naval Aviation and Congressional Fellow for the United States Navy. Mr. Harris received his M.B.A. from the Wharton School of Business, and a B.S. from the United States Naval Academy.
About Inozyme Pharma
Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).
Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these molecules. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases.
For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedIn, X, and Facebook.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation, timing, and design of our planned clinical trials, availability of data from clinical trials, the potential benefits of INZ-701, our regulatory strategy, including our planned pathway to approval for the ABCC6 Deficiency program, and the period over which we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our cash flow requirements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's ability to conduct its ongoing clinical trials of INZ-701 for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis; enroll patients in ongoing and planned trials; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain, and protect intellectual property rights related to its product candidates; manage expenses; comply with covenants under its outstanding loan agreement; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com
Media:
Biongage Communications
Todd Cooper
(617) 840-1637
Todd@biongage.com
FAQ
Who is the new board member appointed by Inozyme Pharma (INZY)?
What experience does Erik Harris bring to Inozyme Pharma's (INZY) board?
Why did Inozyme Pharma (INZY) appoint Erik Harris to its board?
What is the potential impact of Erik Harris joining Inozyme Pharma's (INZY) board?
